Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment
Psychedelics-based treatments developer NeuroPharm Inc., a subsidiary of publicly traded Mydecine Innovations Group Inc., recently announced it would be collaborating with the Leiden University Medical Center of The Netherlands (LUMC) on clinical trials for the treatment of posttraumatic stress disorder (PTSD) in veterans.
The project involves the preparation of an IRB-ready protocol that will later be utilized in the LUMC-based clinical trial. The ARQ National Psychotrauma Centre will also be involved in the trial.
The first compound to be studied will be psilocybin, a psychedelic prodrug compound that can be produced by more than 200 species of mushrooms. The initial protocol will involve three doses in a study spread over 12 weeks.
It is believed this is the first trial of its kind.